An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation

Europace

Volumn 15, Issue 5, 2013, Pages 652-656

  Lewalter, Thorsten ^a   Ibrahim, Réda ^b   Albers, Bert ^c   Camm, A John ^d  

^a Isarklinikum Munich   (Germany)

^b MONTREAL HEART INSTITUTE   (Canada)

^c Albers Clinical Evidence Consultancy ^*  (Netherlands)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atrial fibrillation; Left atrial appendage; Percutaneous occlusion; Stroke prophylaxis

Indexed keywords

BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CARDIOVASCULAR PROCEDURE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; DEVICE SAFETY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION; PRIORITY JOURNAL; REVIEW;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84877312432     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut043     Document Type: Review

References (20)

1. Holmes D, Reddy V, Turi Z, Doshi S, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009;374: 534-42.
2. Reddy V, Holmes D, Doshi S, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 2011;123: 417-24.
3. Reddy V, Neuzil P, Miller M, Schuler G, Möbius-Winkler S, Wiebe J et al. First formal analysis of the 'Asa Plavix Registry' (ASAP): Watchman left atrial appendage closure in atrial fibrillation patients with contraindication to oral anticoagulation. Paper presented at: HRS, 2012, May 9-12; Boston.
4. Walsh K. Left atrial appendage closure with the Amplatzer cardiac plug: results of the European post-market observational study. Paper presented at: Euro PCR, 2012 May 15-18; Paris.
5. Kefer J, Vermeersch P, Budts W, De Potter T, Benit E, Aminian A. Transcatheter percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation: The Belgian Registry. Paper presented at: Euro PCR, 2012 May 15-18; Paris.
6. Meerkin D, Butnaru A, Dratva D, Tzivoni D. One-year outcomes following LAA occlusion in high-risk patients with atrial fibrillation. Paper presented at: Euro PCR, 2012 May 15-18; Paris.
7. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation - initial European experience. Catheter Cardiovasc Interv 2011;77: 700-6.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012;14: 1385-413.
9. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
10. Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: 883-91.
11. Saperas E, Videla S, Dot J, Bayarri C, Lobo B, Abu-Suboh M et al. Risk factors for recurrence of acute gastrointestinal bleeding from angiodysplasia. Eur J Gastroenterol Hepat 2009;21: 1333-9.
12. Gladstone D, Bui E, Fang J, Laupacis A, Lindsay M, Tu J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40: 235-40.
13. Palnum K, Mehnert F, Andersen G, Ingeman A, Krog B, Bartels P et al. Medical prophylaxis following hospitalization for ischemic stroke: age- and sex-related differences and relation to mortality. Cerebrovasc Dis 2010; 30: 556-66.
14. Flaherty M, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007;68: 116-21.
15. Robert-Ebadi H, Righini M. Anticoagulation in the elderly. Pharmaceuticals 2010;3: 3543-69.
16. Goldstein J, Greenberg S. Should anticoagulation be resumed after intracerebral hemorrhage? Cleveland Clin J 2010;77: 791-9.
17. England T, Bath P, Sare G, Geeganage C, Moulin T, O'Neill D et al. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the tinzaparin in acute ischaemic stroke trial. Stroke 2010;41: 2834-9.
18. Mudd P, James M. Anticoagulation for atrial fibrillation: should warfarin be temporarily stopped or continued after acute cardioembolic stroke? Age Ageing 2010;39: 670-3.
19. Guérios E, Schmid M, Gloekler S, Khattab A, Wenaweser P, Windecker S et al. Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. Arq Bras Cardiol 2012;98: 528-36.
20. Viles-Gonzalez J, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R et al. The clinical impact of incomplete left atrial appendage closure with the Watchman device in patients with atrial fibrillation. J Am Coll Cardiol 2012;59: 923-9.